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Oxygen delivery is essential to sustain all vital functions.
Vertebrate organisms have, therefore, evolved sophisticated
and tightly regulated mechanisms to ensure continuous red
cell synthesis. Chronic or acute blood losses trigger multiple
feedbackmechanismsaimedatincreasingerythropoiesisand
minimizing the damage associated with profound anemia
and hypoxia.
Iron is an element of paramount importance for ery-
thropoiesis, being an essential part of the hemoglobin
metalloprotein that ensures oxygen absorption, transport,
and delivery. Therefore, it is not surprising that iron
absorption and transport are closely linked to the demands
of erythropoiesis. However, the mechanisms underlying this
interconnected relationship have only recently started being
understood.
T h ef o c u so ft h i ss p e c i a li s s u ei so ni r o nm e t a b o l i s m ,
erythropoiesis, and their close association, with a special
emphasis on proteins regulating iron metabolism and how
erythropoiesis aﬀects their expression. The mechanistic view
will be integrated with the clinical observations in disease
such as myelodysplastic syndromes, sickle cell anemia,
Diamond-Blackfan anemia, and anemia of inﬂammation.
And ﬁnally, in light of these new discoveries, new potential
therapies for well-known disorders such as beta-thalassemia
will be discussed.
In the last decade, new discoveries have fueled the ﬁeld of
iron metabolism. The papers by H. Li and Y. Z. Ginzburg[1],
E. Nemeth [2], L. Cianetti et al. [3], and T. Tanno and J. L.
Miller [4] provide a comprehensive and updated overview of
the proteins involved in regulating dietary iron absorption,
plasma iron concentrations, tissue iron distribution, and
erythropoiesis. The review by H. Li and Y. Z. Ginzburg
[1] introduces the mechanisms of crosstalk between iron
and erythropoiesis and their function in diﬀerent diseases.
E. Nemeth [2] describes the role of the peptide hormone
hepcidin in iron physiology and in many iron-related dis-
orders and highlights the potential of hepcidin agonists and
antagonist as future therapeutic tools for iron disorders. The
paper by L. Cianetti et al. [3] describes the hepcidin receptor
and iron transporter ferroportin and its role during normal
and pathological erythroid diﬀerentiation. The paper by T.
Tanno and J. L. Miller [4] describes the relationship between
iron regulation and ineﬀective erythropoiesis, focusing on
potential mechanisms for pathological iron overloading.
Improved knowledge on proteins that interconnect iron
metabolism and erythropoiesis is opening new prospective
to develop new therapies, such as in beta-thalassemia.
The review by L. Melchiori et al. [5]p r o v i d e si m p o r t a n t
evidence that use of Jak2 inhibitors or hepcidin agonists may
ameliorate the abnormal erythropoiesis and iron overload in
β-thalassemia.
The interdependence of erythropoiesis and iron reg-
ulation extends beyond normal metabolism to include
several pathological conditions. Diseases that are primarily
associated with erythroid defects often lead to iron overload,
maldistribution, or deﬁciency. The reviews by E. Messa et
al. [6] and by M. A. Badawi et al. [7] summarize the
historical progress and recent clinical developments using
iron chelation in patients with myelodysplastic syndromes.
Similarly, the paper by R. Raghupathy et al. [8]p r o v i d e sa n
overview of transfusional iron overload patients with sickle
cell disease, highlighting how to prevent iron overload in this
disorder.
Diamond-Blackfan anemia is a rare congenital pure red-
cell aplasia that presents during infancy. D. Chiabrando
and E. Tolosano’s [9]r e v i e wf o c u s e du p o nh e m ea n d2 Advances in Hematology
ribosomalbiogenesisinthisdiseaseandwhydeﬁciencyofthe
heme exporter Feline Leukemia Virus subgroup C Receptor
(FLVCR1) may cause a related phenotype.
Finally, the review by E. A. Price and S. L. Schrier [10]
provides a comprehensive and updated overview of anemia
of inﬂammation, focusing on many of key clinical issues that
remain to be clariﬁed, such as understanding of mechanisms
of anemia of inﬂammation in “noninﬂammatory” diseases,
optimal methods for distinguishing anemia of inﬂammation
fromirondeﬁciencyanemia,andunderstandingthecontrib-
utory role of various pathologic mechanisms in individual
human diseases that lead to anemia of inﬂammation.
We hope that this special issue will stimulate curiosity,
interest, and new research directions in exploring the ﬁeld
of iron and erythropoiesis, with the ultimate goal to develop
new drugs and improve the management of disorders associ-
ated with altered iron metabolism, abnormal erythropoiesis,
and anemia of inﬂammation.
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